A Two Part Bioequivalence Study to Compare Two Fixed Dose Combination (FDC) Tablets of Dapagliflozin/Metformin XR 5/500 mg (Part 1) and 10/1000 mg (Part 2) Manufactured at Two Different Plants (Humacao, Puerto Rico and Mount Vernon, US) in Healthy Subjects Under Fasting and Fed Conditions
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Dapagliflozin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 15 Sep 2017 Planned End Date changed from 7 Dec 2017 to 16 Nov 2017.
- 15 Sep 2017 Planned primary completion date changed from 7 Dec 2017 to 16 Nov 2017.
- 17 Jul 2017 New trial record